Literature DB >> 30320954

Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients.

Sara Becker1,2, Alena Bäumer1,2, Walter Maetzler1,3, Susanne Nussbaum1,2, Maarten Timmers4,5, Luc Van Nueten4, Giacomo Salvadore6, Detlev Zaunbrecher7, Benjamin Roeben1,2, Kathrin Brockmann1,2, Johannes Streffer4,5, Daniela Berg1,3, Inga Liepelt-Scarfone1,2.   

Abstract

The core criterion for Parkinson's disease dementia (PDD) is the impairment in activities of daily living (ADL) function primarily caused by cognitive, not motor symptoms. There is evidence to assume that mild ADL impairments in mild cognitive impairment (PD-MCI) characterize those patients at high risk for dementia. Data of 216 Parkinson's disease (PD) patients assessed with comprehensive motor and neuropsychological assessments were analysed. Based on linear regression models, subscores of the Functional Activities Questionnaire (FAQ) primarily reflecting patients' global cognitive status (FAQC ) or PD-related motor severity (FAQM ) were developed. A quotient (FAQQ ) of both scores was calculated, with values >1 indicating more cognitive- compared to motor-driven ADL impairment. Both FAQC and FAQM scores were higher in PD-MCI than cognitively normal (PD-CN) patients, indicating more severe cognitive- and motor-driven ADL impairments in this group. One third (31.6%) of the PD-MCI group had a FAQQ score >1, which was significantly different from patients with PD-CN (p = .02). PD-MCI patients with an FAQQ score >1 were more impaired on tests assessing attention (p = .019) and language (p = .033) compared to PD-MCI patients with lower FAQQ values. The differentiation between cognitive- and motor-driven ADL is important, as the loss of functional capacity is the defining factor for a diagnosis of PDD. We were able to differentiate the cognitive-driven from the motor-driven ADL impairments for the FAQ. PD-MCI patients with more cognitive- compared to motor-driven ADL impairments may pose a risk group for conversion to PDD and can be targeted for early treatments.
© 2018 The British Psychological Society.

Entities:  

Keywords:  Activities of Daily Living; Functional Activities Questionnaire; Parkinson's disease; cognition

Mesh:

Year:  2018        PMID: 30320954     DOI: 10.1111/jnp.12173

Source DB:  PubMed          Journal:  J Neuropsychol        ISSN: 1748-6645            Impact factor:   2.864


  5 in total

1.  Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson's Disease.

Authors:  Eva Schaeffer; Thomas Vaterrodt; Laura Zaunbrecher; Inga Liepelt-Scarfone; Kirsten Emmert; Benjamin Roeben; Morad Elshehabi; Clint Hansen; Sara Becker; Susanne Nussbaum; Jan-Hinrich Busch; Matthis Synofzik; Daniela Berg; Walter Maetzler
Journal:  J Neurol       Date:  2021-02-05       Impact factor: 4.849

2.  Divergence Between Informant and Self-Ratings of Activities of Daily Living Impairments in Parkinson's Disease.

Authors:  Sara Becker; Susanne Solbrig; Katja Michaelis; Bettina Faust; Kathrin Brockmann; Inga Liepelt-Scarfone
Journal:  Front Aging Neurosci       Date:  2022-02-11       Impact factor: 5.750

3.  A New Instrument Combines Cognitive and Social Functioning Items for Detecting Mild Cognitive Impairment and Dementia in Parkinson's Disease.

Authors:  Ya-Wen Yu; Chun-Hsiang Tan; Hui-Chen Su; Chung-Yao Chien; Pi-Shan Sung; Tien-Yu Lin; Tsung-Lin Lee; Rwei-Ling Yu
Journal:  Front Aging Neurosci       Date:  2022-06-16       Impact factor: 5.702

4.  The Instrumental Activities of Daily Living in Parkinson's Disease Patients Treated by Subthalamic Deep Brain Stimulation.

Authors:  Ondrej Bezdicek; Josef Mana; Filip Růžička; Filip Havlik; Anna Fečíková; Tereza Uhrová; Evžen Růžička; Dušan Urgošík; Robert Jech
Journal:  Front Aging Neurosci       Date:  2022-06-17       Impact factor: 5.702

5.  Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease.

Authors:  Brenna Cholerton; Kathleen L Poston; Lu Tian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; Krista Specketer; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord Clin Pract       Date:  2019-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.